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Pregnane X receptor (PXR, NR1I2) belongs to the nuclear receptor superfamily of 
ligand-activated transcription factors and was identified in 1998.  PXR is highly expressed in the 
liver and intestine, and is involved in regulating the expression of genes that encode important 
drug metabolizing enzymes as well as several key drug transporter proteins.  Previous studies 
have found that ligand-mediated activation of PXR can increase the expression of multidrug 
resistance protein 1 (Mdr1) in the endothelial cells in the intestine in mice.  However, there is no 
correlation between PXR activation and Mdr1 gene expression levels in liver hepatocytes in 
these animals.  Thus, PXR biology exhibits a curious phenomenon in that there appears to be a 
tissue-specific role of this nuclear receptor superfamily member.  Currently, the molecular 
mechanism(s) underlying this phenomenon are not known, but we hypothesize here that tissue-
specific PXR-binding and co-regulatory/accessory proteins likely play a key role in governing 
this phenomenon.  While liver and intestine express high levels of PXR, other tissues have been 
found to express lower but significant levels of this nuclear receptor protein including kidney, 
ovary, stomach, and brain.   
Several lines of evidence support the notion of a key role for PXR in regulating brain 
function.  First, the expression of PXR was identified in 2004 in brain capillary endothelial cells.  
Lower levels of PXR were also detected in several brain regions of different species including 
rat, rabbit, pig, human, and mouse.  Several key endogenous neurosteroidal compounds, 
including allopregnanolone, have been demonstrated to serve as PXR-ligands to dramatically 
increase the trans-activation capacity of this nuclear receptor family member.  Finally, the 
proestrous rats infused with PXR anti-sense oligonucleotides to the ventral tegmental area 
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significantly decreased levels of allopregnanolone, further suggesting an interface between PXR 
and allopregnanolone metabolism. 
Therefore, the purpose of the research described in this thesis is (1) to develop a method 
for the identification of tissue-specific PXR-binding proteins, and (2) to characterize the 
potential effects of PXR deletion and PXR activation on the expression of the genes that encode 
the rate limiting enzymes in the production of allopregnanolone in mice.  In the first study, I 
developed a novel protocol using adenovirus-mediated methods coupled with primary cultures of 
rat hepatocytes and liquid chromatography-tandem mass spectrometry (LC-MS/MS) to identify 
hepatocyte-specific PXR-binding proteins.  In the second study, I tested the hypothesis that PXR 
can regulate 5α-reductase type 1 (Srd5α1) and type 2 (Srd5α2) gene expression levels in mouse 
brain.  My results reveal that deletion of PXR in mice alters basal expression levels of Srd5α1 
and Srd5α2 in a tissue-specific manner.  Additionally, Pregnenolone 16α-carbonitrile (PCN) 
decreased Srd5α1 and Srd5α2 gene expression in the liver and several brain regions in both wild 
type and PXR knockout mice, suggesting that PCN-mediated decrease of Srd5α1 and Srd5α2 
gene expression is in a PXR-independent manner.  
Taken together, the data presented in this thesis shed new light upon the role of PXR in 
regulating the expression of key target genes in the brain.  In particular, the data suggest that 
while PXR plays a role in neurosteroid metabolism, there is also a key PXR-independent role in 
neurosteroid metabolism in several brain tissue types following exposure to steroidal compounds 
such as PCN.  Finally, the biochemical procedures developed and validated in this thesis should 
be useful in identifying novel PXR-binding proteins from primary cultures of neuronal cells, as 
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CHAPTER 1: INTRODUCTION 
Pregnane X receptor (PXR, NR1I2) is a ligand-activated transcription factor that belongs 
to nuclear receptor (NR) superfamily. PXR has a wide range of ligands including lipids, bile 
acids, and different xenobiotics. Upon activation, PXR binds to a DNA sequence and then 
regulates its target gene expression.  
Similar to other NRs, PXR has a DNA binding domain and a ligand binding domain 
connected by a hinge region. The DNA binding domain allows PXR to bind to regulatory DNA 
sequences and therefore regulate transcription process. The ligand binding domain allows PXR 
to bind to its ligand, dimerize with other nuclear receptors as well as interact with transcriptional 
co-factors [1]. PXR binds to RXR as a heterodimer to form a transcriptionally active complex [2-
3]. When inactive, PXR-RXR forms a complex with corepressor proteins to inhibit 
transcriptional activity. Activation of PXR by ligands causes a conformational change, resulting 
in PXR disassociating from its co-repressors. PXR-RXR then recruits coactivators to enhance 
gene transcription. The main coactivator of PXR is steroid receptor coactivator-1 (SRC-1) and 
the main co-repressors are silencing mediator for retinoid or thyroid-hormone receptors (SMRT), 
and nuclear receptor corepressor (NcoR) [4-5].  
PXR plays a key role in different kinds of human health problems, including drug-drug 
interaction, lipid homeostasis, inflammatory based disorders, cancer, and chemotherapeutic 
resistance.  
PXR is highly expressed in the liver and intestine, and can regulate the expression level 
of phase I P450 enzymes, phase II drug conjugation enzymes and phase III drug transporters [6-
11]. Among them are the CYP3A4 enzymes which can metabolize more than 50% of the 
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clinically used drugs [12] and CYP2B6 which contributes to 10% of the metabolism of clinically 
used drugs. Therefore, increases in these enzymes, by PXR activation, contributes to the turnover 
of drugs, and thus, causes drug-drug interactions.  
PXR target genes are also involved in lipid metabolism. Activation of PXR chronically 
increases cholesterol and atherogenic low density lipoprotein (LDL) and very-low density 
lipoprotein (VLDL) plasma levels in wild-type (WT) mice. This effect was abolished in PXR-
knockout (PXR-/-) mice [13], suggesting that PXR plays a role in lipid metabolism. The human 
immunodeficiency virus (HIV) protease inhibitor (PI) Amprenavir has been shown to increase 
plasma total cholesterol and atherogenic low density lipoprotein cholesterol levels in wild-type 
mice, and this effect was totally abolished in PXR-deficient mice. Amprenavir activated PXR 
and induced CYP3A4, UGT1A1, and MDR1 gene expression in both human hepaRG hepatoma 
cells and LS180 intestinal cells [14]. 
PXR additionally contributes to the inflammatory response. Activation of mouse PXR by 
PCN repressed the NF-κB target genes expression in the dextran sulfate sodium (DSS)-induced 
inflammatory bowel disease (IBD) mouse model [15]. The interaction between NF-κB p65 and 
RXR DNA binding domain may inhibit the transactivation by the PXR/RXR complex [16]. 
Dubrac et al found that PXR expression is increased in T-lymphocytes, a marker of 
inflammation, following immune activation [17] and activation of PXR inhibits T-lymphocyte 
proliferation by decreasing the expression of CD25 and IFN-ɣ [17]. These studies indicate that 
PXR activation can suppress inflammatory responses. Chronic inflammation can precede cancers 
including hepatocellular carcinoma (HCC), colon cancer (CAC) and gastric cancer [18-19].  
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The roles of PXR are variable in different cancer tissue types.  On the one hand, 
activation of PXR shows enhanced cell growth and invasion in human colon cancer xenograft 
mouse models [20], and protects colon cancer LS180 cells from apoptosis [21]. Activation of 
PXR also protects HepG2 human hepatoma cells from apoptosis [22]. These results suggest that 
PXR has an anti-apoptotic role in carcinogenesis. On the other hand, PXR shows a pro-apoptotic 
effect on endometrial and breast cancers [23-24]. Therefore these indicate that PXR has tissue-
specific and cancer type-specific functions.  
PXR activation can cause chemotherapy resistance. Chemotherapy is one of the major 
treatments for cancer. However, a large number of the patients experienced multidrug resistance 
(MDR) during chemotherapy. Jiang et al found that activation of PXR by Rif increased the 
resistance of colon cancer cells to chemotherapeutics, and shRNA-induced reduction of PXR 
increased sensitivity of LS174T colon carcinoma cells to chemotherapeutics [25]. In prostate 
cancer, activation of PXR caused chemotherapeutic resistance and shRNA-based down-
regulation of PXR resulted in sensitization toward chemotherapeutic agents, mirroring what was 
found in colon cancer [26]. All-trans-retinoic acid (ATRA) is a chemotherapeutic agent used for 
treatment of acute promyelocytic leukemia (APL) [27]. PXR ligands administrated with ATRA 
can increase ATRA metabolism by increasing CYP3A expression therefore causing ATRA 
resistance [28].  These results suggest that inhibition of PXR could be a target for reducing 
resistance to chemotherapeutics.  
Recently, a low level of PXR expression has been detected in the brain in different 
species. PXR was found involved in Alzheimer’s disease pathology [29]; activation of PXR 
delays the progression of neurodegeneration in human Niemann–Pick type C1 (NPC1) disease, a 
neurodegenerative disease related to the inability to process cholesterol [30]. Moreover, knock 
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down of PXR decreased levels of allopregnanolone, an endogenous neurosteroid, which led to 
behavior changes in mice [31]. These indicate that certain type of neurosteroid may activate PXR 
and regulate PXR function in the brain.  
 
Statement of Purpose 
The PXR protein is highly expressed in both liver and intestine where it plays a key role 
in drug, steroid, and bile acid metabolism. Recently, a low level of PXR expression has been 
detected in the brain indicating the possibility that PXR may play a role in metabolic brain 
function, and perhaps in the pathogenesis of neuronal diseases. However, the precise role of PXR 
in the brain remains unknown.   Based on these previous studies, we hypothesize that certain 
neurosteroids can activate PXR and regulate the expression of vitally important brain-specific 
PXR-target genes that function in mediating this clinically important phenomenon. 
Understanding this mechanism may play a key role in finding new drug targets for many 
neurological diseases.  
To date, activation of PXR in the liver and intestines is known to be achieved by 
numerous compounds including certain steroids, bile acids, natural products, and numerous 
drugs [32-34]. The increased expression of genes targeted by PXR encodes biochemically linked 
drug- and steroid-processing proteins that function to regulate the homeostasis of these 
compounds.   For example, PXR activation up-regulates the activity of vital drug and steroid 
metabolizing enzymes, as well as key drug transporter proteins [35-36].   Drug metabolizing 
enzymes targeted by PXR include Cytochrome P450 (CYP) proteins CYP3A, CYP2B, and 
CYP2C [37-38].   PXR activation up-regulates the expression of genes encoding essential drug 
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and bile acid transporters including key members of the multidrug resistance-associated protein 
(MRP) and multidrug resistance protein (MDR) families of membrane transporter proteins.   
For this proposal, it is noteworthy that PXR activation dramatically increases the 
expression of Mdr1/P-Gp in the intestine [39]. However, there is no significant correlation 
between MDR1 expression level and PXR activation in the liver [40]. Taken together, this 
phenomenon illustrates the now widely accepted notion that PXR has tissue-specific functions as 
evidenced by the differential and tissue-specific regulation of its target genes. Currently, the 
molecular mechanism(s) responsible for this phenomenon are unknown. We hypothesize that the 
tissue-specific PXR co-regulatory protein environment likely mediates the tissue-specific 
function of PXR and is responsible for the differential regulation of its target genes in different 
tissues. 
Our overall goal is to identify (1) tissue-specific PXR co-regulatory proteins and (2) 
brain-specific PXR-target genes. 
In order to discover PXR-associated proteins, we transduced rat hepatocytes with 
adenovirus Ad-(His)6-human PXR for 48 hours to achieve a high level of expression of PXR. 
Together with a non-transduced control group, cells were harvested and the nuclei were extracted 
in hypotonic buffer. The (His)6-tagged PXR protein and its associated proteins were enriched by 
immobilized metal affinity chromatography (IMAC). Subsequently, enriched proteins were 
separated by SDS-PAGE gel and Liquid chromatography-tandem mass spectrometry (LC-
MS/MS) detection was performed to identify proteins. 
Total RNA was isolated by TRIZOL reagent, and reverse transcription- polymerase chain 
reaction (RT-PCR) assay was used to detect qualitative expression of genes encoding PXR, 
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selected CYPs, as well as several key drug transporter proteins in seven mouse brain regions 
including amygdala, prefrontal cortex, hippocampus, hypothalamus, mid-brain, striatum, and 
cerebellum.  Subsequently, an in vivo study was utilized to understand PXR’s role in brain.   
Mouse PXR ligand PCN or corn oil as a control was injected intraperitoneally into wild-type and 
PXR-KO mice for 3 consecutive days. On day 4, mice were euthanized and brain regions were 
dissected and frozen in -80 ℃. RNA was isolated from these brain regions. Total RNA isolated 
from liver was also be used as a positive control group for known PXR-target gene induction.  
Quantitative real-time PCR (RT-QPCR) was used to quantitatively detect the expression of PXR 
in brain as well as selected known and potential PXR-target genes including those encoding key 
5α-reductase enzymes Srd5α1 and SrR5α2.    
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CHAPTER 2: A NOVEL METHOD TO IDENTIFY PXR BINDING PARTNERS 
Introduction 
Cancer is one of the major health problems in the United States. In 2016, an estimated 
1,685,210 people were diagnosed as new cancer cases in the United States and around 595,690 
people died from cancer [41]. Chemotherapy is one of the most common treatments for cancer. 
However, the efficacy of chemotherapy is limited because of the multidrug resistance (MDR) 
phenomenon [42], which is characterized as decreased drug concentrations in the cells as well as 
a decreased cancer cell response [43].  MDR often causes the failure of chemotherapy and 
eventually leads to the death. An estimated of 500,000 new cases of cancer will experience MDR 
each year [44].  
MDR can be developed by multiple pathways, including decreased drug influx, increased 
drug efflux and activated drug detoxification metabolism pathways [45]. Multidrug resistance 
protein 1 (MDR1, also known as P-glycoprotein 1, P-gp) is an ATP-dependent transmembrane 
drug efflux transporter. MDR1 is expressed not only in the liver, intestine, kidney, but also in the 
brain. MDR1 can functionally protect the human body from xenobiotics by pumping them back 
into the bile ducts, urine, intestinal lumen as well as capillaries in the brain. However, this 
function can also cause failure of chemotherapy treatment in cancer. Thus, MDR1 
overexpression is considered as a major cause of multidrug resistance leading to insufficient drug 
concentrations in cells [46]. This phenomenon was confirmed in many tumor cells including 
colon, kidney, breast, liver and pancreatic cells [47]. This suggests that the inhibition of MDR1 
could be a strategy for overcoming drug resistance.  
First generation inhibitors of MDR1 including quinine, cyclosporine A, and verapamil 
are already approved by the Food and Drug Administration (FDA), but show toxic side effects at 
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sufficient MDR1 inhibition doses [48-49]. Second generation inhibitors of MDR1, such as PSC-
833, decreased the toxic side effects; however, also decreased the drug clearance systemically 
and increased the exposure of both normal tissue and cancer tissue to toxic drugs at the same 
time [50]. Therefore, the investigation of second generation inhibitors of MDR1 has been 
stopped due to high mortality rates [51]. Third generation inhibitors of MDR1 focused on 
increasing the affinity of MDR1 binding as well as decreasing the toxicity [52]. The 
investigations of third generation inhibitors are still ongoing. However, universal inhibition of 
MDR1 may still cause undesired and uncontrolled toxicity in the human body. Thus, it is 
necessary to find an alternative mechanism to decrease MDR1 expression or activity in order to 
overcome MDR.  
MDR1 is known to be regulated by nuclear receptor PXR. Upon activation, PXR 
heterodimerizes with RXR to form an active complex to regulate target genes transcription 
processes [53]. Several groups found that PXR activation can significantly increase the 
expression of MDR1 in the intestine, but not in the liver [54]. The mechanism of this 
phenomenon remains unknown. However, it provides a new basis to regulate tissue-specific 
MDR1 expression, thus may offer new therapies for overcoming MDR.  
PXR has a DNA-binding domain, a ligand-binding domain containing an activation 
function 2 region (AF2). The structure of AF2 allows PXR to recruit different transcriptional 
coregulatory proteins, including coactivators and co-repressors, which play critical roles in gene 
regulation processes. Thus we hypothesized that the tissue-specific PXR co-regulatory protein 
environment likely mediates the tissue-specific function of PXR and is responsible for the 
differential regulation of its target genes in different tissues. Here we reported a novel method to 




Materials and Methods 
Plasmids and chemicals  
The human PXR adenovirus was generated as previously described [55]. Briefly, PXR 
STOP codon was removed and EcoRV and Xho I restriction enzyme sites were introduced by 
PCR using (His)6-tagged PXR as a template. PCR product was inserted into the multiple cloning 
sites in pShuttle IRES-hrGFP expression vector. Then human PXR adenovirus was generated as 
previously described [56].  
Isolation and culturing of primary rat hepatocytes 
Adult male rats were allowed water and maintained on standard laboratory chow for one 
week. Primary hepatocytes were isolated from live rats using a standard collagenase perfusion 
procedure and the medium was replaced with serum-free Williams E medium four hours later as 
previously described [57].  
Adenovirus infection and GFP fluorescence detection 
Four 15-cm plates of non-transduced hepatocytes were used as a control group and four 
15-cm plates of hepatocytes were infected with Ad-(His)6-hPXR (0.8 µl/plate). After 48 hours, 
GFP expression was observed and recorded using a fluorescence microscope.  
Nuclei and cytosol fraction separation 
Each plate of cells were harvested with 1.5 mL PBS containing protease inhibitors 
(Fisher, A32965) and centrifuged at 240 x g for 10min at 4 °C. Cell pellets were lysed by 5 pellet 
volumes of hypotonic buffer (Table 1) and centrifuged at 106 x g for 10 min at 4°C. The 
supernatant was saved as cytosol fraction, and the pellet as nuclei fraction.  
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Immobilized metal affinity chromatography assay 
Nuclear fraction was re-suspended in 1.5 mL lysis buffer (Table 1) containing protease 
inhibitors and homogenized to mix thoroughly. Cobalt beads were pre-washed with lysis buffer 
and were added to each tube, agitated for 2 hours at 4°C to allow the cobalt beads to bind to 
(His)6-tagged proteins. Then samples were centrifuged at 425 x g for 1 min at 4°C, and washed 
with 1 mL wash buffer (Table 1) for 3 times by centrifuging at 425 x g for 1 min each time. 30 
µL 2x SDS sample buffer (with 50 mM DTT) was added to each sample tube.   
Coommassie blue staining, silver staining and western blot analysis  
Proteins were resolved on 4-15% gradient SDS-polyacrylamide gel electrophoresis gels 
and coommassie blue staining was performed by adding coommassie blue dye and agitating for 
30 min. Then the gel was de-stained in ddH2O for 10 min and saved for LC-MS/MS assay. 
Proteins were also resolved on 4-15% gradient SDS-polyacrylamide gel electrophoresis gels and 
transferred to polyvinylidene difluoride microporous membranes (Millipore Bioscience Research 
Reagents) that were probed with anti-PXR antibody (H-11, Santa Cruz). Silver staining was 
performed as previously described [58].   
Liquid chromatography-tandem mass spectrometry analysis 
The LC–MS/MS analysis for identifying PXR binding proteins was performed as 
described previously [59]. Briefly, bands were cut and digested by trypsin, and then analyzed by 
LC-MS/MS.   
Results  
PXR overexpression by adenoviral infection  
In order to increase hPXR expression in cells and limit adenovirus toxicity, time course 
and tittering experiments of Ad-(His)6-hPXR were performed in HepG2 and Hepa1-6 cells (data 
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not shown) to determine adenovirus amount and transduction time. Primary rat hepatocytes were 
isolated and cultured as described and the experiment design is shown in Figure 1. In order to 
achieve high expression of human PXR to exceed the LC-MS/MS detection limitation, we used 4 
15-cm plates of hepatocytes as an experimental group, and another 4 plates as control. Cells in 
experimental group were infected with Ad-(His)6-hPXR for 48 hours. Together with control 
group, cell morphology and GFP protein expression were observed and recorded using a 
fluorescence microscope. Because of the characteristics of internal ribosome entry site (IRES) in 
adenovirus expression vector, after translation, the expression of PXR protein should be more 
than 10 times the GFP protein expression. We achieved high expression levels of human PXR in 
hepatocytes (Figure 2). In addition, there was no significant difference in cell viability between 
the experimental group and control group, which suggests that our transduction method is 
efficient and non-toxic to primary hepatocytes.   
Enrich PXR and binding proteins by IMAC 
The string of histidine residues can bind to cobalt beads under specific buffer conditions 
and can be used to enrich (His)6-tagged proteins. We tried to perform immobilized metal affinity 
chromatography assays using whole cell lysates. However, the coomassie blue staining showed 
that numerous background proteins were also pulled down with cobalt beads (data not shown), 
indicating high level of non-specificity as well as high background for LC-MS/MS analysis 
assay. Upon activation, PXR is mainly located in the nuclei to regulate target gene transcription, 
so our proteins of interest should be located mainly in nuclei. We decided to use a biochemical 
method to extract the nuclei fraction from whole cell lysate and therefore to reduce background 
signals. Fractions were resolved and separated on 4-15% gradient SDS-PAGE gel, and 
coomassie blue staining showed that we significantly reduced background signal (Figure 3). We 
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used nuclei marker, nucleoporin 62 (Nup62), and cytosol marker, lactate dehydrogenase (LDH), 
to further confirm the efficiency of biochemical separation. Western blotting showed a 
successful separation between nuclei and cytosol fraction (Figure 3).  
Mild buffer conditions (Imidazole and Tween-20) were used in lysis and washing buffers 
and all the samples were kept at 4 °C or on ice during the procedure to preserve the binding 
between PXR and its associated proteins. Immobilized metal affinity chromatography was 
performed with 25 µL sample of each group resolved and separated on 4-15% gradient SDS-
PAGE gel. Compared with control group, the PXR overexpression group showed a significant 
enrichment of PXR proteins (Figure 4) in coomassie blue staining, and western blotting with 
anti-PXR antibody H-11 further confirmed this result (Figure 4). Many more bands appeared in 
the PXR overexpression group as compared to the control group in coomassie staining gel, 
which we think were potential PXR associated proteins.  
The sensitivity limit of coomassie blue, in this case, instant blue, is 5 ng. Thus, proteins 
less than 5 ng cannot be visualized with coomassie blue staining. Sliver staining, however, is 
much more sensitive than coomassie blue, and can detect proteins as low as 0.25 ng/ µl. 
Therefore, we used silver staining to visualize lower concentrations of proteins as a guide for the 
LC-MS/MS assay. As expected, there were some bands detected with silver staining but not with 
coomassie blue, especially proteins larger than 180 kDa (Figure 5). Based on these results, we 
decided to use LC-MS/MS assay guided by silver staining to detect potential PXR associated 
proteins. LC-MS/MS assay was performed and multiple candidate PXR-binding proteins were 




In this study, we designed a novel method to identify PXR-binding partners that uses 
adenovirus-mediated overexpression of PXR in primary cultured rat hepatocytes. Non-
denaturing IMAC-mediated purification methods are coupled with LC-MS/MS to identify co-
purified PXR-binding partners. Coomassie blue and silver staining showed high levels of 
enrichment of exogenously added PXR and its likely binding proteins, thus our buffer conditions 
are useful tools for this novel non-denaturing IMAC assay. Using this method, we identified 
Retinoid X receptor α (RXRα) as a heterodimeric partner of PXR. This is important because 
RXRα serves as the protein partner of numerous liver-enriched nuclear receptors including CAR, 
LXR, PPAR, as well as PXR [60]. The RXRα protein is expressed at high levels in liver, 
intestine, and kidney tissues [61]. Hence, this result lends a high level of confidence that our 
experimental approach is valid.  
Of note, the TATA box binding protein (TBP)-associated factors (TAF) including TAF2, 
TAF5, and TAF6 were also identified as potential PXR binding partners in this study. TBP-
associated factors contribute to the RNA polymerase II pre-initiation complex when bound with 
TBP [62]. Previously, nuclear receptors such as RXRα [63], progesterone receptor [64], and 
vitamin D receptor [65] were found to interact with this complex to increase the rate of 
transcription initiation. TAFs function as mediators between nuclear receptors and basal 
transcription factors in this process. Thus, it is highly likely that we isolated these proteins as a 
part of a multi-protein complex using PXR as a bait protein in this assay. These data lend further 
confidence in the validity of our methods.  
Several novel candidate PXR-binding proteins including Prohibitin 1, Prohibitin 2, and 
Jun D, were also identified (Table 2). Prohibitins are involved in cell proliferation [66], survival, 
apoptosis [67], and signaling. Prohibitins, also known as PHB, are ubiquitously expressed and 
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divided into two classes called PHB1 and PHB2. They have been suggested to interact with 
different nuclear receptor proteins to modulate their transcriptional activity. While PHB2 binds 
to estrogen receptor α (ERα) to repress its transactivation capacity [68], PHB also has a 
repressive effect on the androgen receptor (AR) [69]. In addition, PHB interacts with the 
important nuclear receptor co-regulatory proteins Nuclear Co-Repressor (NCoR), and histone 
deacetylase 1 (HDAC1). Additionally, PHB interacts with retinoblastoma (Rb) to repress E2F 
family transcriptional activities [70-71]. As discussed previously, NCoR and HDAC1 are also 
well-known PXR co-regulatory binding proteins. Thus, it is highly possible that PHB is part of a 
multi-protein complex to regulate the transactivation capacity of PXR.  
JunD is a transcription factor that belongs to JUN family. JunD functions as a coactivator 
of the nuclear receptor AR to form a complex that can bind to AR target gene to regulate its 
transactivation capacity [72]. It is therefore possible that JunD could also interact with the 
nuclear receptor PXR to modulate its transactivation capacity. Further research is necessary to 
determine the extent to which this is true.  
Another potential binding partner identified is Ring finger protein 2 (RNF2), which is 
expressed in different cancer types including breast cancer [73], ovarian cancer [74], and 
pancreatic cancer [75]. To date, there is no evidence showing that RNF2 can interact with any 
nuclear receptors. It would therefore be interesting to investigate RNF2’s biological function in 
terms of binding to and regulating PXR activity.    
In comparison with other methods used to identify protein partners such as yeast two-
hybrid system, the method we developed here has several distinct advantages. First, our method 
utilized primary hepatocytes, or other primary cell types, with an appropriate cellular 
background. This fact allows for the identification of endogenous co-regulatory proteins from a 
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pertinent repertoire of potential protein partners. In other words, binding partners are identified 
from a wild type context. Second, our method utilized full length PXR, as opposed to the 
artificial fusion of the GAL4-DBD and the PXR-LBD as occurs in the yeast two-hybrid system. 
Finally, our system allows for the use of PXR ligands, both agonists and antagonists, in the 
context of a wild type milieu.   
In comparison with another commonly used method, transfection activity based 
enrichment of PXR and its binding proteins, our method using adenoviral infection assay has a 
high efficiency in terms of overexpression of PXR proteins. Instead of using HeLa cells, our 
method allows the use of wild type primary cultured cell types and therefore is useful for 
identifying tissue-specific PXR binding proteins.  
Taken together, these data indicate that our method is valid for the identification of PXR-
associated proteins from primary cultured hepatocytes, and can likely be used to identify tissue-
specific PXR-binding partners in primary cultured cells isolated from other tissue types such as 
the primary cultures of enterocytes and neuronal cells. Future studies should commence with co-
immunoprecipitation methods to further confirm binding between PXR and candidate PXR-
binding proteins. Besides, the human PXR ligand, rifampicin, could be added to this assay in 
order to identify ligand-dependent PXR binding proteins. In addition, PXR co-regulatory 
proteins that can respond to inflammation can also be identified using stimulated cells under 




Table 1 Buffer condition 
 
Lysis buffer 
pH = 8.0 
NaH2PO4 50 mM 
NaCl 300 mM 
Imidazole 10 mM 
Tween 20 0.05% 
Wash buffer 
pH = 8.0 
NaH2PO4 50 mM 
NaCl 300 mM 
Imidazole 20 mM 
Tween 20 0.05% 
Hypotonic Buffer Tris (pH=7.7) 10 mM 
MgCl2 1.5 mM 




Table 2 Identified candidate PXR-binding proteins 
 
Identified Proteins Peptides Identified 
heat shock protein 70 34 
Cyclin-dependent kinase 9 21 
Prohibitin  1 11 
Retinoid X receptor alpha 7 
TAF5 RNA polymerase II, TATA box binding protein (TBP)-associated 
factor 
6 
Cyclin-dependent kinase 12 isoform X1 5 
Prohibitin 2 4 
Jun D proto-oncogene 4 
pre-mRNA-splicing regulator WTAP isoform a 4 
Rbmx2 protein 4 
Chaperonin containing Tcp1, subunit 3 (gamma) 4 
TAF2 RNA polymerase II, TATA box binding protein (TBP)-associated 
factor 
3 
Ring finger protein 2 3 
TAF6 RNA polymerase II, TATA box binding protein (TBP)-associated 
factor, isoform CRAa 
3 
Chaperonin containing TCP1, subunit 2 (beta) 2 









Figure 1. Experimental design. Liver perfusion was performed in live rats to get rat 
hepatocytes. Cells were infected with Ad-(His)6-hPXR-FLAG adenovirus for 48 hours, and lysed 
with non-denaturing lysis buffer. Nuclear fraction was extracted using a biochemical method, 
followed by immobilized metal affinity chromatography. Coomassie staining and Western 
blotting were performed to visualize PXR and its binding proteins. Liquid chromatography-
tandem mass spectrometry (LC/MS/MS) was performed to identify PXR binding partners.   
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Figure 2. Adenovirus infection assay. Primary rat hepatocytes were isolated and transduced 
with Ad-hPXR for 48 hours; cell morphology and GFP expression were detected using 
fluorescence microscope. Ø: Non-transduction control group, Ad-PXR: adenoviral infection 
group, GFP: GFP fluorescence in adenoviral infection group. Compared with the left panel, the 
middle panel showed that PXR adenovirus didn’t cause significant cell damage, therefore is not 
toxic to hepatocytes in this dosage. GFP fluorescence showed a high overexpression of PXR 
protein.  
  
Ø Ad-PXR GFP 
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Figure 3  
 
Figure 3. Biochemical separation validation. Hypotonic buffer was used to separate nuclei and 
cytosol fractions after cell lysis under native condition. Coomassie staining and western blotting 
were used to validate the efficiency of nuclear and cytosol fraction biochemical separation before 
immobilized metal affinity chromatography. Ø: no treatment control group, ad-hPXR: PXR 
infection group, Nup62: Nucleoporin 62, a nuclei marker; LDH: Lactate dehydrogenase, a 
cytosol marker.  
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Figure 4  
 
Figure 4. Coomassie staining and Western blotting. Immobilized metal affinity 
chromatography was performed under native condition in nuclear fraction. Coomassie Staining 
and Western Blotting were used after IMAC to visualize PXR and its binding protein before 
LC/MS/MS. Ø: control group, Ad-hPXR: adenoviral infection group. Compared with control 
group, Ad-PXR group showed a strong enrichment of PXR proteins (58kDa). Western blotting 
with anti-PXR antibody (H-11) further confirmed this result.  
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Figure 5  
 
Figure 5. Silver staining and Western Blotting. Silver staining and Western Blotting were 
performed after IMAC to visualize PXR and its binding proteins before LC/MS/MS. Ø: control 
group, Ad-PXR: adenoviral infection group. Compared with control group, more bands were 
appeared in Ad-PXR group with silver staining, especially proteins larger than 118kDa, 
suggesting an efficient enrichment and purification of PXR-binding proteins. Western blotting 




CHAPTER 3: THE EFFECTS OF PXR ACTIVATION AND DELETION ON 5α-
REDUCTASE GENE EXPRESSION  
Introduction 
PXR was initially identified as a nuclear receptor highly expressed in the liver and 
intestine, with low levels of expression in the kidney and stomach. However, recently PXR has 
been identified in the brain of multiple different species. Bauer et al. detected PXR expression in 
rat whole-brain homogenates and in isolated brain capillaries using RT-PCR [76]. They further 
confirmed this result by immunostaining rat brain capillaries with a PXR antibody. This is the 
first evidence showing the existence of PXR in the brain. The expression of PXR was confirmed 
in the mid brain of rats [77], human thalamus, medulla, pons and spinal cord [78], rabbit cortex 
[79], and mouse cerebellum, hypothalamus, and thalamus [80]. The role of PXR in the brain 
remains unknown; however, several studies found that PXR is involved in neurosteroid 
homeostasis.  
Allopregnanolone is an endogenous neurosteroid which can bind to the GABAA receptor 
and regulate neurotransmission. At low concentration, allopregnanolone potentiates GABAA 
receptor currents, but does not cause direct activation. However, at high concentrations, it can 
directly activate the receptor [81-82]. There are two different GABAA receptors: synaptic 
GABAA receptor and extrasynaptic GABAA receptor. Activation of these two receptors can 
cause phasic inhibition and tonic inhibition respectively. Allopregnanolone can modulate both 
synaptic and extrasynaptic GABAA receptors to potentiate phasic and tonic inhibition and has 
large effects on extrasynaptic δ-subunit GABAA receptors [83-85]. The extrasynaptic GABAA 
receptors are distributed within the hippocampus, neocortex, thalamus, striatum, hypothalamus, 
and cerebellum [86]. Increasing of the biosynthesis of allopregnanolone can be used to treat 
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posttraumatic stress disorder, anxiety and depression [87]. Down-regulation of allopregnanolone 
biosynthesis in the midbrain is responsible for anxiety, aggression and reduced reproductive 
behavior in socially isolated mice [88].  
Mice treated with allopregnanolone subcutaneously for 24 hours showed an increased 
PXR mRNA level in hypothalamus and thalamus in the brain [89]. Female mice infused of PXR 
antisense oligonucleotides (AS-ODNS) to the ventral tegmental area significantly suppressed 
estradiol-enhanced reproductive behavior [90], demonstrating an important role of PXR in 
regulating reproductive behavior in the mice. Frye et al found that knocking down of PXR by 
AS-ODNS in the midbrain significantly reduced allopregnanolone levels in the midbrain and 
hippocampus, suggesting that PXR may be involved in the formation of allopregnanolone in the 
brain [91-92]. 
Allopregnanolone is synthesized from progesterone by cortical and hippocampus 
pyramidal neurons and pyramidal-like neurons of the basolateral amygdala in the brain [93]. 
Progesterone is reduced by 5α-reductase to form 5α-dihydroprogesterone, which can later be 
converted to allopregnanolone by 3α-hydroxysteroid dehydrogenase (3α-HSD). 5α-reductase is 
the rate-limiting enzyme in this synthesis process. The family of 5α-reductases contains three 
isoenzymes: 5a-reductase type 1 (SRD5α1), 5a-reductase type 2 (SRD5α2) and 5a-reductase type 
3 (SRD5α3). To date, SRD5α1 and SRD5α2 are present in all species examined and well 
characterized [94]. However, knowledge of SRD5α3 enzymatic activity is limited and its natural 
steroid substrates are largely unknown. Recently, SRD5α3 has been found lacking steroid 5a-
reductase activity and cannot reduce progesterone to 5α-dihydroprogesterone in either human or 
hamster [95]. Thus, the reduction of progesterone is mainly regulated by SRD5α1 and SRD5α2. 
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Here we hypothesized that PXR may regulate allopregnanolone levels through regulating Srd5α1 
and Srd5α2 gene expression in brain.  
Materials and methods 
Drug preparation  
Pregnenolone 16α-carbonitrile (PCN) (Sigma) was dissolved in corn oil (Sigma) and the 
final concentration is 40 mg/ml. The drug was stored at 4 °C, and vigorously shake or vortex 
before use.  
Animal treatment administration  
WT and PXR-KO male mice (6-week old) were divided into 4 groups, named as WT 
Vehicle, WT PCN, PXR-knock out (PXR-KO) Vehicle and PXR-KO PCN. Each group has 6 
mice. Mice were administered vehicle (corn oil 0.11 cc/10g) or PCN (PCN 40 mg/ml, 0.11 
cc/10g) via intraperitoneal injection for consecutive three days. On day four, mice were 
euthanized and liver as well as seven brain regions (hypothalamus, amygdala, prefrontal cortex, 
hippocampus, striatum, mid brain and cerebellum) were isolated and frozen in -80℃.  
RNA isolation  
We combined two mice together for a total of three samples for each brain region. 
Tissues were dissolved in 300 µl (for brain) or 500 µl (for liver) TRIZOL (Invitrogen) 
respectively and homogenized. After centrifuging at 4 °C at 20817 x g for 10 min, the 
supernatant was carefully transferred into a new tube and 180 µL chloroform was add into each 
tube. After shaking vigorously, sample was centrifuged at 4 °C at 20817 x g for 15 min. Then the 
upper aqueous phase of each sample was carefully collected and an equitable amount of 
isopropanol (around 100 µl) was added to each sample. After centrifugation, the pellet was 
washed by 70% ethanol twice. The tubes were then placed in a 37°C incubator for 5 - 10 minutes 
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to dry. Then the RNA was dissolved in 20µL ddH2O via pipetting. The absorbance value at 
260nm was used to quantify RNA.   
1 % RNA agarose gel 
1% RNA agarose gel electrophoresis was performed to assess the integrity of RNA. 
Agarose (0.6g) was added into 48 mL ddH2O and microwaved for 1 min until the agarose was 
fully dissolved. 37% formaldehyde (6 mL) and 6 mL 10X MOPS (20 mM EDTA, 200 mM 
MOPS, 50 mM Sodium acetate, pH = 7.0) were added into solutions and mixed thoroughly. Gel 
solution was poured and stabilized in gel electrophoresis set for at least 30 min.  
Each sample contains 6.5 µl ddH2O, 2.5 µl 4x RNA loading buffer (50% glycerol, 1mM 
EDTA, 0.4% bromophenol blue, 1mg/ml ethidium bromide) and around 1 µg RNA. Samples 
were heated in 60 °C for 5 min before loading. Electrophoresis was performed in 90V for 60 
min, and 2X MOPS (4 mM EDTA, 40 mM MOPS, 10 mM Sodium acetate, pH = 7.0) was used 
as running buffer.  
Reverse Transcription 
1 µg of RNA was reversed-transcribed by using random primers following the 
manufacturer’s instruction (Promega). Samples were first incubated at room temperature for 10 
minutes. Then samples were heated at 42°C for 60 minutes and followed by heating at 95°C for 
5 minutes. The final products were stored at 4°C for later use.  
Polymerase chain reaction  
Equal amounts of cDNA were used in polymerase chain reactions (PCR). Reactions 
contained 300 nM primers specific for mouse PXR (Table 3). The PCR assay was performed as 
previously described [96].  
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Quantitative real-time polymerase chain reaction 
Quantitative real-time polymerase chain reaction was performed as previously described 
[97]. Briefly, reactions contained 1X SYBR green (Lonza Rockland, Inc., Rockland, ME) and 
300 nM primers specific for β-actin, Cyp3a11, Oatp2, Srd5α1 and Srd5α2 (Table 3) respectively. 
Each sample was analyzed in triplicate. The mRNA levels of Cyp3a11, Oatp2, Srd5α1 and 
Srd5α2 were normalized to a housekeeping gene β-actin using the formula as following: ΔCT 
(test gene) = CT (test gene) - CT (β-actin). Then ΔΔCT of each gene was used to represent the 
relative mRNA induction levels using the formula as following: ΔΔCT (test gene) = ΔCT (test 
gene) - ΔCT (test gene in WT Veh group). For Cyp3a11 and Oatp2, the fold changes of gene 
expression were represented by the value of 2- ΔΔCT (test gene). For Srd5α1 and Srd5α2, the 
percentage changes of gene expression were represented by the value of 100*2- ΔΔCT (test 
gene) (%).  
8% DNA polyacrylamide gel 
8% DNA polyacrylamide gel electrophoresis [98] was performed to visualize PXR 
amplification as well as detect Srd5α1 and Srd5α2 primer sets (Table 3) specificity. Each sample 
contained 9 µl of PCR or quantitative real-time PCR products and 1 µl of 10X DNA loading 
buffer [98]. Electrophoresis was performed in 120V for 80 min. Then gel was stained in 
ethidium bromide (EB) for at least 20 min followed by visualization of the amplification bands 
under UV light.  
Data analysis and statistics 
All quantitative real-time RT- PCR data were analyzed by two-way analysis of variance 
(ANOVA) using a statistical program (GraphPad Prism, version 6.02) followed by Tukey’s 
multiple comparisons post-hoc test. A p value of < 0.05 was considered significant. The data are 
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presented as mean of fold change ± standard error of the mean (SEM) for Cyp3all and Oatp2 in 
liver. For Srd5α1 and Srd5α2, the data are presented as mean of percent change ± SEM. 
Results 
PXR mRNA level in wild type mice brain 
We examined RNA integrity using 1% RNA agarose gel, which showed high quality of 
RNA (Figure 6A). Then RT-PCR was performed and PXR mRNA expression was detected in 
8% DNA polyacrylamide gel. Using liver and PXR plasmid (pCMV-tag2B-mPXR-fl) as positive 
controls and ddH2O as negative control, we detected PXR mRNA in all seven brain regions 
(Figure 6B). This result indicates that PXR is expressed in seven brain regions in mRNA level.  
The effects of PXR activation and deletion on Cyp3all, Oatp2, Srd5α1 and Srd5α2 
expression in liver 
We used PCN, a well-known selective mouse PXR ligand, to activate PXR in mice to see 
if PXR activation has any effects on Srd5α1 and Srd5α2 gene expression in the liver and brain. 
WT and PXR-KO mice were treated with either corn oil or PCN daily for three days. On day 
four, mice were sacrificed and the liver and different brain regions were dissected and RNA was 
isolated. First, we looked at RNA integrity of total 48 samples. Our result showed high quality of 
RNA (Figure 7).  
Using quantitative real-time RT-PCR assay, we detected two prototypical PXR target 
genes, Cyp3a11 and Oatp2, in the liver. As expected, we found that the treatment of PCN 
dramatically increased Cyp3all (Figure 8A) and Oatp2 (Figure 8B) gene expression in the liver 
in WT, and this effect was totally abolished in PXR-KO group. These data showed that PCN can 
increase Cyp3a11 and Oatp2 gene expression in the liver in a PXR-dependent manner, and are 
consistent with previous studies [99].  
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Srd5α1 and Srd5α2 primer sets were also validated, as shown in Figure 8C-D. 
Quantitative real-time RT-PCR of Srd5α1 and Srd5α2 was performed in WT mice in the 
hypothalamus and liver, and 8% DNA polyacrylamide gel was used to visualize amplification of 
the result. Our result showed high specificity of Srd5α1 and Srd5α2 primer sets.   
We then detected Srd5α1 and Srd5α2 gene expression in the liver. Our results showed 
that deletion of PXR altered Srd5α1 basal level in liver, and PCN treatment decreased Srd5α1 
expression in both WT and PXR-KO group (Figure 8E). Treatment of PCN reduced Srd5α2 
gene expression level in the PXR-KO group but not in the WT group, and the deletion of PXR 
also altered Srd5α2 basal level (Figure 8F). These data suggests that Srd5α1 and Srd5α2 are not 
PXR target genes in the liver and PCN-induced decrease of Srd5α1 and Srd5α2 gene expression 
is in a PXR-independent manner.  
The effects of PXR activation and deletion on Srd5α1 and Srd5α2 expression in 
brain  
The quantitative real-time RT-PCR assays were performed in seven brain regions: 
hypothalamus, amygdala, PFC, hippocampus, striatum, mid brain and cerebellum. As shown in 
Figure 9A-G, no significant change of Srd5α1 gene expression was seen with the activation or 
deletion of PXR in the seven brain regions. Thus, Srd5α1 gene expression is not regulated by 
PXR in the seven brain regions.  
We found that activation or deletion of PXR didn’t cause any significant change in 
Srd5α2 expression in the amygdala (Figure 10B), PFC (Figure 10C), hippocampus (Figure 10 
D), striatum (Figure 10E), or mid brain (Figure 10F). In the hypothalamus, deletion of PXR 
altered the Srd5α2 gene basal level, however the activation of PXR did not cause any significant 
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change (Figure 10A). In the cerebellum, treatment of PCN in PXR-KO mice dramatically 
increased Srd5α2 gene expression in comparison with the PXR-KO vehicle group (Figure 10 G). 
In summary, our data showed that 1) PXR mRNA is expressed in the hypothalamus, 
amygdala, PFC, hippocampus, striatum, mid brain and cerebellum in the mouse; 2) knockout of 
PXR increased Srd5α1 basal level in the liver, and the treatment of PCN decreased Srd5α1 
mRNA level in both wild type and PXR-KO group in the liver, However, there is no significant 
change of Srd5α1 in the brain in these groups; 3) knockout of PXR increased Srd5α2 basal level 
in both the liver and hypothalamus. The treatment of PCN decreased Srd5α2 expression in PXR-
KO in liver, on the contrary, increased Srd5α2 expression in PXR-KO group in cerebellum.  
Discussion 
Our study showed for the first time that PXR was expressed in seven brain regions at a 
low mRNA level. However, we didn’t look at the protein levels of PXR in these brain regions. In 
the future studies, immunohistochemistry can be used to determine PXR protein expressions in 
these brain region tissues.  
Previous studies showed that knocking down of PXR decreased allopregnanolone level in 
the midbrain and hippocampus. However, from our results, we found that deletion of PXR can 
alter the basal levels of Srd5α1 and Srd5α2 in the liver, and the basal Srd5α2 in the 
hypothalamus. Thus, Srd5α1 and Srd5α2 are not PXR target genes in either the liver or brain and 
other mechanisms should be responsible for PXR knockdown-induced decrease of 
allopregnanolone level. As discussed previously, two major enzymes involved in the 
biosynthesis of allopregnanolone from progesterone are 5α-reductase and 3α-Hydroxysteroid 
dehydrogenase (3α-HSD). Previously study found that activation of PXR by rifampicin in human 
PXR-transgenic mice can significantly increase the expression of 3β-HSD, another member of 
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hydroxysteroid dehydrogenase enzymes, in the adrenal glands [100]. Therefore, it is possible that 
PXR can regulate 3α-HSD expression in the brain to regulate allopregnanolone levels. Future 
studies should commence with testing this hypothesis.  
According to our results, PXR activation or deletion did not have any effects on Srd5α1 
expression in seven brain regions. Interestingly, treatment of PCN, a prototypical mouse PXR 
ligand, led to reduced Srd5α1 gene expression in both WT and PXR-KO groups in the liver. 
These two different results from the brain and the liver suggest that 1) Srd5α1 is not a PXR 
target gene in the brain and 2) PCN-induced decrease of Srd5α1 in the liver is carried out in a 
PXR-independent manner. We hypothesized that PCN may have some feedback suppression 
effects on Srd5α1 and Srd5α2, which could explain PCN-induced decrease of Srd5α1 and 
Srd5α2 in the liver.  It is known that PCN is a synthesized steroid and shares the same core 
structure with allopregnanolone (Figure 11). As discussed previously, Srd5α1 and Srd5α2 are 
rate-limiting enzymes of the allopregnanolone synthesis process. Thus, it is possible that 
allopregnanolone and PCN is responsible for some feedback suppression on Srd5α1 and Srd5α2 
expression.  
Surprisingly, in PXR-KO group, PCN treatment in the cerebellum significantly increased 
Srd5α2 gene expression compared with the vehicle-treated group, indicating other mechanisms 
may be involved in this phenomenon. For decades, PCN has been considered as a selective 
mouse PXR ligand. However, recently, PCN was found to have immunosuppressive activity 
independent of PXR activation in mouse liver [101]. Although the mechanism underlying this 
phenomenon is unknown, it is noteworthy that other nuclear receptors such as Glucocorticoid 
receptor (GR), liver X receptor (LXR), Farnesoid X receptor (FXR) and Constitutive androstane 
receptor (CAR) are also involved in the liver immune system. Thus, PCN might interact with 
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other nuclear receptors to suppress immune activity. Among many NRs, thyroid hormone 
receptor alpha (THRA), thyroid hormone receptor beta (THRB), and LXRs were found to be 
highly expressed in the cerebellum [102]. LXRs are master regulators of cholesterol homeostasis 
in the brain [103], and progesterone can be synthesized from cholesterol. Therefore, it is possible 
that other nuclear receptor, such as LXR, may interact with PCN to regulate Srd5α2 gene 
expression in the cerebellum. Further studies are necessary to test this possibility. Due to the fact 
that some of the quantitative real-time RT-PCR data have large error bars, it is hard to draw 
reliable conclusions from these data. Therefore, in the feature study the same experiments need 






Table 3. Primer sets sequences. 
Srd5α1 Left primer:  5’ gAg TTg gAT gAg TTg CgC CTA 3’ 
Right primer: 5’ ggA CCA CTg CgA ggA gTA g 3’  
Srd5α2  Left primer: 5’ gAT CCT gTg CTT Tgg gAA ACC 3’ 
Right primer: 5’ gCA TCC CTA CCg ACA CCA C 3’ 
Cyp3a11 Left primer: 5’ CAA ggA gAT gTT CCC TgT CA 3’ 
Right primer: 5’ CCA CgT TCA CTC CAA ATg AT 3’ 
PXR Left primer: 5’ gAT ggA ggT CTT CAA ATC TgC C 3’ 
Right primer: 5’ ggC CCT TCT gAA AAA CCC CT 3’ 
Oatp2  Left primer: 5’ TTg CTg ACT gCA ACA CAA Ag 3’ 
Right primer: 5’ Tgg TTC CAg TTC CAA CAg AC 3’ 
β-actin Left primer: 5’ CAA gAT CAT TgC TCC TCC Tg 3’ 












































Figure 6. PXR mRNA level in wild type mice brain. Wild type male mice were sacrificed and 
seven brain regions as well as liver were isolated. RNA was extracted and RT-PCR was 
performed. (A) 1% RNA agarose gel electrophoresis was performed with RNA isolated from 
brain regions and liver. (B) 8% DNA polyacrylamide gel was used to visualize amplification 




Figure 7  




















Figure 7. RNA integrity of brain regions and liver samples. Mice were treated with PCN or 
corn oil as control respectively. RNA were extracted and examined in 1% RNA agarose gel. (A): 
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liver, (B): hypothalamus, (C): amygdala, (D): PFC, (E): hippocampus, (F): striatum, (G): mid 
brain, and (H) cerebellum. 1-3: WT Veh; 4-6: WT PCN; 7-9: PXR-KO Veh; 10-12: PXR-KO 
























Figure 8. The effects of PXR activation and deletion on Cyp3all, Oatp2, Srd5α1 and Srd5α2 
expression in liver. Quantitative real-time RT-PCR was performed in liver samples. (A) Cyp3all 
gene expression in liver. Two-way ANOVA shows a significant main effect of gene deletion: 
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F(1,8)=9.075, p=0.0167, a significant main effect of treatment (PCN): F(1,8)=14.92, p=0.0048 
and a significant interaction between treatment and gene deletion: F(1,8)=13.9, p=0.0058. Post 
hoc by Tukey’s multiple comparisons test indicates treatment of PCN in WT significantly 
increased Cyp3all level (**p<0.005) and treatment of PCN in KO significantly decreased 
Cyp3all compared with WT (#p<0.05). n=3 (B) Oatp2 gene expression in liver. Two-way 
ANOVA shows a significant main effect of gene deletion: F(1,8)=96.32, p<0.0001, a significant 
main effect of treatment (PCN): F(1,8)=83.18, p<0.0001 and a significant interaction between 
treatment and gene deletion: F(1,8)=76.11, p<0.0001. Post hoc by Tukey’s multiple comparisons 
test indicates treatment of PCN in WT significantly increased Oatp2 level (****p<0.0001) and 
treatment of PCN in KO significantly decreased Oatp2 compared with WT (####p<0.0001). n=3 
(C) Validation of Srd5α1 primer set. Quantitative real-time RT-PCR was performed in wild type 
mouse hypothalamus and liver. Amplification size: 123bp. (D) Validation of Srd5α2 primer set. 
Quantitative real-time RT-PCR was performed in wild type mouse hypothalamus and liver. 
Amplification size: 134bp. (E) Srd5α1 gene expression in liver. Two-way ANOVA shows a 
significant main effect of gene deletion: F (1, 8) = 168.1, P<0.0001, a significant main effect of 
treatment (PCN): F (1, 8) = 46.72, P=0.0001 and interaction between treatment and gene 
deletion: F (1, 8) = 0.5, P=0.4996. Post hoc by Tukey’s multiple comparisons test indicates 
knockout of PXR significantly increased basal level of Srd5α1 (####p<0.0001) and treatment of 
PCN significantly decreased Srd5α1 gene expression in both WT (*p<0.05) and PXR-KO 
(&&p<0.005). n=3 (F) Srd5α2 gene expression in liver. Two-way ANOVA shows a significant 
main effect of gene deletion: F (1, 8) = 58.23, P<0.0001 a significant main effect of treatment 
(PCN): F (1, 8) = 42.89, P=0.0002 and a significant interaction between treatment and gene 
deletion: F (1, 8) = 38.3, P=0.0003. Post hoc by Tukey’s multiple comparisons test indicates 
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deletion of PXR significantly increased basal level of Srd5α2 (####p<0.0001) and compared with 
Veh, treatment of PCN significantly decreased Srd5α2 gene expression in PXR-KO 








































































































































































Figure 9  
 

























Figure 9. The effects of PXR activation and deletion on Srd5α1 gene expression in brain. 
Quantitative real-time RT-PCR was performed in seven brain regions as described previously. 
(A) hippocampus Two-way ANOVA shows no significant main effect of gene deletion: 
F(1,8)=2.455, p=0.1558, no significant main effect of treatment (PCN): F(1,8)=0.1212, p=0.7367 
and no significant interaction between treatment and gene deletion: F(1,8)=1.939, p=0.2012. n=3 
(B) amygdala Two-way ANOVA shows no significant main effect of gene deletion: 
F(1,8)=4.024, P=0.0798, no significant main effect of treatment (PCN): F (1, 8) = 0.5952, 
P=0.4626 and no significant interaction between treatment and gene deletion: F (1, 8) = 0.02381, 
P=0.8812. n=3 (C) PFC Two-way ANOVA shows no significant main effect of gene deletion: F 
(1, 8) = 1.354, P=0.2780, no significant main effect of treatment (PCN): F (1, 8) = 0.7619, 
P=0.4082 and no significant interaction between treatment and gene deletion: F (1, 8) = 0.3386, 
P=0.5767. n=3 (D) hippocampus Two-way ANOVA shows no significant main effect of gene 
deletion: F (1, 8) = 0.01404, P=0.9086, no significant main effect of treatment (PCN): F (1, 8) = 
0.07644, P=0.7892 and no significant interaction between treatment and gene deletion: F (1, 8) = 
0.01404, P=0.9086. n=3 (E) striatum Two-way ANOVA shows no significant main effect of 
gene deletion: F (1, 8) = 0.18, P=0.6826, a significant main effect of treatment (PCN): F (1, 8) = 
5.78, P=0.0429 and no significant interaction between treatment and gene deletion: F (1, 8) = 
1.62, P=0.2388. Post hoc by Tukey’s multiple comparisons test shows no significance. n=3 (F) 
mid brain Two-way ANOVA shows a significant main effect of gene deletion: F (1, 8) = 6, 
P=0.0400, no significant main effect of treatment (PCN): F (1, 8) = 0.1667, P=0.6938 and no 
significant interaction between treatment and gene deletion: F (1, 8) = 0.6667, P=0.4379. Post 
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hoc by Tukey’s multiple comparisons test shows no significance. n=3 (G) cerebellum Two-way 
ANOVA shows no significant main effect of gene deletion: F (1, 8) = 0.1088, P=0.7499, no 
significant main effect of treatment (PCN): F (1, 8) = 0.6803, P=0.4334 and no significant 
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Figure 10  
 
























Figure 10. The effects of PXR activation and deletion on Srd5α2 gene expression in brain. 
Quantitative real-time RT-PCR was performed in seven brain regions as described previously. 
(A) hippocampus Two-way ANOVA shows a significant main effect of gene deletion: F (1, 8) = 
10.95, P=0.0107, a significant main effect of treatment (PCN): F (1, 8) = 5.313, P=0.0501 and no 
significant interaction between treatment and gene deletion: F (1, 8) = 2.438, P=0.1570. Post hoc 
by Tukey’s multiple comparisons test indicates deletion of PXR significantly increased Srd5α2 
basal level (#p<0.05). n=3 (B) amygdala Two-way ANOVA shows no significant main effect of 
gene deletion: F (1, 8) = 2.841, P=0.1304, no significant main effect of treatment (PCN): F (1, 8) 
= 1.885, P=0.2070 and no significant interaction between treatment and gene deletion: F (1, 8) = 
1.288, P=0.2892. n=3 (C) PFC Two-way ANOVA shows no significant main effect of gene 
deletion: F (1, 8) = 1.354, P=0.2780, no significant main effect of treatment (PCN): F (1, 8) = 
0.7619, P=0.4082 and no significant interaction between treatment and gene deletion: F (1, 8) = 
0.3386, P=0.5767. n=3 (D) hippocampus Two-way ANOVA shows a significant main effect of 
gene deletion: F (1, 8) = 10.01, P=0.0133, no significant main effect of treatment (PCN): F (1, 8) 
= 0.002274, P=0.9631 and no significant interaction between treatment and gene deletion: F (1, 
8) = 0.006318, P=0.9386. Post hoc by Tukey’s multiple comparisons test indicates no 
significance. n=3 (E) striatum Two-way ANOVA shows a significant main effect of gene 
deletion: F (1, 8) = 7.129, P=0.0284, no significant main effect of treatment (PCN): F (1, 8) = 
1.191, P=0.3068 and no significant interaction between treatment and gene deletion: F (1, 8) = 
2.653, P=0.1420. Post hoc by Tukey’s multiple comparisons test indicates no significance. n=3 
(F) mid brain Two-way ANOVA shows a significant main effect of gene deletion: F (1, 8) = 
6.32, P=0.0361, no significant main effect of treatment (PCN): F (1, 8) = 1.235, P=0.2988 and no 
significant interaction between treatment and gene deletion: F (1, 8) = 1.024, P=0.3413. Post hoc 
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by Tukey’s multiple comparisons test indicates no significance. n=3 (G) cerebellum Two-way 
ANOVA shows a significant main effect of gene deletion: F (1, 8) = 14.97, P=0.0047, a 
significant main effect of treatment (PCN): F (1, 8) = 7.834, P=0.0232 and a significant 
interaction between treatment and gene deletion: F (1, 8) = 10.22, P=0.0127. Post hoc by 
Tukey’s multiple comparisons test indicates treatment of PCN significantly increased Srd5α2 















CHAPTER 4: DISSCUSSION 
Previous studies have reported that PXR showed tissue-specific functions in terms of 
regulating its target genes. Activation of PXR can significantly increase MDR1 gene expression 
as well as protein level in the intestine. However, PXR activation didn’t cause any change of 
MDR1 gene expression in the liver. Recently, PXR was also found to express in the brain in 
different species, and showed brain-specific functions. PXR is involved in the regulation of 
neurosteroid levels and therefore involved in the pathology of different neurodegenerative 
diseases and mental disorders. Although the precise mechanism of PXR performing tissue-
specific functions is currently unknown, it is notable that PXR function as a transcription factor 
through binding to co-regulatory proteins and form a complex to initiate a transcription process. 
To date, different co-activators and co-repressors of PXR have been discovered. Thus we 
hypothesized that tissue-specific co-regulatory proteins may lead to tissue-specific PXR 
functions.  
In the present study, I mainly focused on two parallel projects. In my first project, I used 
a novel method to identify PXR co-regulatory proteins in the liver. PXR protein were 
overexpressed in primary cultured rat hepatocytes using adenoviral infection assay, coupled with 
immobilized metal affinity chromatography assay in native condition to enrich PXR and its 
binding proteins. LC-MS/MS assay was used to identify protein peptides. Besides a well- known 
PXR binding partner RXRα, several potential binding partners were also identified, including 
prohibitin 1, prohibitin 2, Ring finger protein 2, zinc finger protein and different TATA box 
binding protein (TBP)-associated factors. In this study, I designed and validated buffer 
conditions that are specific for IMAC in non-denaturing conditions, which can be used in the 
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future for studying protein-protein interactions. This study provides a new basis for identifying 
PXR-binding partners in primary cells.  
In future studies, co-immunoprecipitation should be used to further confirm the 
interaction between PXR and different potential binding partners. Additionally, in order to 
explain PXR tissue-specific functions, the LC-MS/MS experiment can be performed in primary 
cells isolated from other tissue types such as primary cultured enterocytes or neuronal cells. Then 
by comparing with the result we generated from the liver, tissue-specific binding partners might 
also be identified. Ligand-dependent PXR co-regulatory proteins can also be identified by adding 
PXR ligands in this assay. Moreover, PXR co-regulatory proteins that can respond to 
inflammation can also be identified using stimulated primary cultured cells under stress 
condition.  
While the first project identified PXR binding partners in the rat liver, my second project 
characterized PXR function in the brain, and specifically, the effects of PXR on Srd5α1 and 
Srd5α2 gene expression in different brain regions. In this study, WT and PXR-KO mice were 
treated with either corn oil as vehicle control, or PCN daily for consecutive three days. On day 4, 
mice were euthanized and the liver and brain regions were isolated. RT-PCR and quantitative 
real-time RT-PCR were performed with RNA isolated from these samples respectively. My 
results showed that Cyp3all and Oatp2 expression increased dramatically upon PXR activation, 
and PCN regulates Cyp3all and Oatp2 in a PXR-dependent manner, which is consistent with the 
results previously generated from our lab [104]. Our studies have demonstrated for the first time 
that 1) PXR is expressed in mRNA level in the hypothalamus, amygdala, PFC, hippocampus, 
striatum, midbrain and cerebellum in the mouse brain. 2) Srd5α1 and Srd5α2 are not PXR target 
genes in either liver or brain in the mouse and PCN-mediated decrease of Srd5α1 and Srd5α2 
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gene expression in the liver is likely through other mechanisms. 3) PCN can induce an increase 
of Srd5α2 gene expression in the cerebellum. Although the mechanism underlying this 
phenomenon is unknown, we hypothesized that other nuclear receptors such as LXR may be 
involved in this regulation process.  
In the future, the role of PXR in terms of regulating 3α-HSD gene expression in the brain 
can be investigated to further explain the mechanism of knocking down PXR-mediated decrease 
of allopregnanolone level in the midbrain and hippocampus. In addition, the role of LXR in this 
process should also be investigated.  
While in the first project, we mainly focused on the PXR binding partners in the liver, our 
second project focused on studying the PXR function in the brain. Our two projects characterized 
PXR biology across different tissues and through different methods, thus, providing scientists 
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